Based on TCGA data, it showed that ASGPR is overexpressed in HCC compared to normal tissues (Figure 1H). This makes the use of glycosylated-PEG-oHSV a highly promising potential therapeutic agent for HCC, with an expected enhancement in efficacy and specificity. Here, ASGR1 is linked to hepatocellular carcinoma.